UK pharmaceutical giant AstraZeneca has entered into an exclusive license agreement with China's CSPC Pharmaceutical Group CSPC to advance the development of an early stage, novel small molecule Lipoprotein a Lpa disruptor that has the potential to offer additional benefits for patients with dyslipidaemia, according to a media release.
Dysplipideamia is when someone has unhealthy levels of lipid fatty compounds in the blood.
CSPC will receive an upfront payment of $100 million from AstraZeneca. CSPC is also eligible to receive up to $1.92 billion for further development and commercialisation milestones, plus tiered royalties, under the agreement.
The aim...
¬ Haymarket Media Limited. All rights reserved.
